Capecitabine
Rectal Diseases
Cancer Institute and Hospital, Chinese Academy of Medical SciencesSmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
2 Active assets in the Rectal Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
pf-08634404 Pfizer | Phase 3 | B |
Eloxatin Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | B |
Catequentinib Zhejiang University | Phase 2 | B |
Ddavp Laboratorio Elea Phoenix S.A. | Phase 2 | NR |
Same molecule, other indications
Capecitabine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →